WHO Updates Essential Medicines List for Hemophilia and VWD: Louise Bannon Applauds Global Hematology Community’s Achievement
Louise Bannon, Director of Membership, Marketing and External Relations of ISTH, shared a post on LinkedIn:
”In today’s news!
WHO Updates Essential Medicines List to Improve Care for People with Bleeding Disorders
The World Health Organization (WHO) has updated its Essential Medicines List (EML) and Essential Medicines List for Children (EMLc) to better align with international clinical guidelines for the management of hemophilia and von Willebrand Disease (VWD).
These revisions will help ensure that decision makers worldwide are guided by the latest evidence when selecting and financing essential medicines, improving access to safer and more effective therapies for people with bleeding disorders (PWBDs).
Key updates include:
- New medicines added: Bi-specific monoclonal antibody emicizumab; recombinant FVIII and FIX clotting factor concentrates (CFCs)
- Existing medicines upgraded: Plasma-derived FVIII and FIX CFCs and desmopressin moved from the complementary to the core list
- Medicines removed: Pathogen-reduced and non-pathogen-reduced cryoprecipitate and Factor IX Complex (PCC)
Congratulations to the global hematology community for advocating strongly to achieve these revisions, ensuring that people with bleeding disorders have access to modern, safe, and effective therapies.
ISTH applauds the leadership of the World Federation of Hemophilia (WFH) and its partners for mobilizing this milestone effort and supporting equitable treatment access worldwide.”
Find the latest news in the World of Bleeding Disorders featured in Hemostasis Today.
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?
-
Nov 8, 2026, 17:36Paschalis Evangelidis: The Multifactorial Nature of Cardiovascular Risk in People With Hemophilia
-
Nov 8, 2026, 17:32Evangelos Panagiotopoulos: Apixaban Reduces Stroke and Major Bleeding Risk in Secondary Stroke Prevention
-
Nov 8, 2026, 17:27Danny Gaskin: Applications Open for the BBTS Specialist Certificate in Clinical Transfusion Practice
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week